Caitlin Miller
Executive Director - Alzheimer’s Disease HCP Marketing TwoStep Therapeutics
Caitlyn Miller, PhD, is CEO and Co-Founder of TwoStep Therapeutics, where she leads the company’s mission to bring innovative targeted therapies to patients. Dr. Miller received her PhD in Bioengineering from Stanford University in the labs of Dr. Carolyn Bertozzi and Dr. Jennifer Cochran. During her PhD and postdoctoral work, Dr. Miller played a pivotal role in advancing technology that is now integrated into TwoStep’s therapeutic pipeline. Dr. Miller then joined the Stanford Innovative Medicines Accelerator as an Entrepreneur-in-Residence, where she led the spinout of TwoStep Therapeutics. Under her leadership, TwoStep is advancing a pipeline of peptide-based drug conjugate and radioligand programs, with its first program now in clinical development.
Seminars
- Outlining the latest trends across the ADC landscape in 2027 and future vision to develop and deliver novel ADCs with meaningful patient impact with safety and efficacy
- Highlighting methods to best pursue ADC clinical differentiation across patient selection technologies, combination strategies, and well-executed clinical design
- With clinical trials advancing in the Far East and Australia, what opportunities does this open for the ADC industry to progress faster?
- Presenting the scientific rationale for a multi-specific targeting agent “PIP” and how it enables broad applicability across solid tumours
- Preclinical development of PIP-drug conjugates, their efficacy and safety, and comparison to clinical benchmarks
- Comparing the data from a single vs multi-targeted approach to highlight the rationale of multi-specific targeting
